Zymeworks Deal Expands Jazz’s Potential Oncology Presence

 
• By Alaric DeArment
  
Zymeworks and Jazz signed a deal worth up to $1.76bn for the HER2-targeting bispecific antibody zanidatamab • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer